MEDI Harbor Health Care ETF

ETF on NYSE (US) · Actively managed · Listing

Daily holdings file Nov 12, 2026 Published at harborcapital.com
Book $43.5M 45 positions
Line items 45
In top 10 65%
Largest holding: Eli Lilly and Company ($9.33M) 21.4%
Portfolio date Nov 12, 2026

Changes appear once four weeks of holdings are on file.

Largest holding: Eli Lilly and Company, 6,543 shares ($9.33M).

Eli Lilly and Company: 21.4% Ascendis Pharma A/S: 17.1% argenx SE: 5.1% Vaxcyte, Inc.: 3.5% Guardant Health, Inc.: 3.4% Insmed Incorporated: 3.1% Rhythm Pharmaceuticals, Inc.: 3.1% United Therapeutics Corporation: 3.0% Revolution Medicines, Inc.: 2.7% IDEXX Laboratories, Inc.: 2.6% The other 35 positions: 34.8% $43.5M Holdings value
Current positions Top 10 % of book
Eli Lilly and Company LLY $9.33M 21.4%
Ascendis Pharma A/S ASND $7.47M 17.1%
argenx SE ARGX $2.24M 5.1%
Vaxcyte, Inc. PCVX $1.53M 3.5%
Guardant Health, Inc. GH $1.48M 3.4%
Insmed Incorporated INSM $1.37M 3.1%
Rhythm Pharmaceuticals, Inc. RYTM $1.37M 3.1%
United Therapeutics Corporation UTHR $1.32M 3.0%
Revolution Medicines, Inc. RVMD $1.19M 2.7%
IDEXX Laboratories, Inc. IDXX $1.11M 2.6%

Slices are % of holdings value.

Healthcare: 98.4% Financial Services: 1.6% 2 sectors
Sectors % of holdings value
Healthcare 98.4%
Financial Services 1.6%
Biotechnology: 53.9% Drug Manufacturers - General: 24.0% Diagnostics & Research: 5.5% Medical Devices: 3.8% Medical Distribution: 3.1% Medical Instruments & Supplies: 2.6% Healthcare Plans: 1.7% Other (4): 5.5% 11 industries
Industries % of holdings value
Biotechnology 53.9%
Drug Manufacturers - General 24.0%
Diagnostics & Research 5.5%
Medical Devices 3.8%
Medical Distribution 3.1%
Medical Instruments & Supplies 2.6%
Healthcare Plans 1.7%
Other (4) 5.5%

Source: the fund's own published holdings, the portfolio of Nov 12, 2026 (harborcapital.com). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.

Objective

The Fund seeks long-term growth of capital.

Principal investment strategies

The Fund invests primarily in equity securities, principally common and preferred stocks of companies of any market capitalization. Under normal market conditions, the Fund invests at least 80% of its net assets, plus borrowings for investment purposes, in securities of companies principally engaged in the research, development, production, or distribution of products and services related to the health care industry ("health care companies"). Health care companies may include, for example, manufacturers of health care equipment and supplies, health care services providers, pharmaceutical companies, biotechnology and life sciences companies, and suppliers of technologies for use by health care companies. The Fund may invest in issuers of all market capitalizations, including larger, established issuers and newer companies with little or no current revenues. The Fund may invest in foreign securities (including through investment in depositary receipts), with such investments typically representing less than 35% of the Fund's net assets. Westfield Capital Management, Company, L.P. ("Westfield" or the "Subadvisor"), the Fund's subadvisor, uses a bottom-up process to identify primarily U.S. listed health care companies that meet the Subadvisor's strict fundamental criteria and then performs a qualitative review on each identified company to select approximately 30 to 50 companies for inclusion in the Fund's portfolio. The Subadvisor considers a number of factors in the course of its fundamental research, including but not limited to valuation, competitive advantage, market opportunity, financial metrics, capital structure, and management track record of execution. The Subadvisor's research may include personal interviews and other contact with company management. In constructing the Fund's portfolio, the Subadvisor seeks to identify health care companies that it believes possess the following characteristics: ■ Superior company management; ■ Corporate governance that aligns with shareholder value creation; ■ Unique market positions and broad market opportunities; and ■ Solid financial controls and accounting processes. The Subadvisor may sell a security if the security reaches or falls below a predetermined price target, a change in the company's fundamentals negatively impacts the Subadvisor's original investment thesis, or the Subadvisor identifies what it believes to be a more attractive investment opportunity. The Fund is classified as non-diversified, which means the Fund may invest in the securities of a smaller number of issuers than a diversified fund. 1 Summary Prospectus Harbor Health Care ETF The Fund concentrates its investments (i.e., holds more than 25% of its total assets) in the securities of issuers in the health care industry or group of industries.

Management and Contact

Adviser
Harbor Capital Advisors, Inc.
Sub-adviser
Westfield Capital Management, Company, L.P.
Portfolio managers

The portfolio managers are jointly and primarily responsible for the day-to-day investment decision making for the Fund.

William A. Muggia Westfield Capital Management Company, L.P. Mr. Muggia is the President, Chief Investment Officer, Chief Executive Officer, a Portfolio Manager and Managing Partner of Westfield and has co-managed the Fund since 2022.

Matthew R. Renna Westfield Capital Management Company, L.P. Mr. Renna is a Partner, Head of the Health Care Sector Team, and a Portfolio Manager of Westfield and has co-managed the Fund since 2022.

Phone
800-422-1050

Track Record as of Dec 31, 2025

1 Year Since Inception
Russell 3000® Growth Health Care Index^^ 21.87% 13.50%
S&P 500 Index^ 17.88% 20.88%

Holdings as of Nov 12, 2026

46 lines, 45 linked, weights sum to 100.00% · Actively managed (N-CEN)

Holding Ticker / identifier Type Shares Weight Market value
ELI LILLY & CO LLY 532457108 Equity 6,543 21.10% $ 9.327M
ASCENDIS PHARMA A/S ASND 04351P101 Equity 27,953 16.90% $ 7.465M
ARGENX SE - ADR ARGX 04016X101 Equity 2,285 5.10% $ 2.242M
VAXCYTE INC PCVX 92243G108 Equity 23,584 3.50% $ 1.526M
GUARDANT HEALTH INC GH 40131M109 Equity 9,568 3.40% $ 1.482M
INSMED INC INSM 457669307 Equity 11,610 3.10% $ 1.371M
RHYTHM PHARMACEUTICALS INC RYTM 76243J105 Equity 12,452 3.10% $ 1.368M
UNITED THERAPEUTICS CORP UTHR 91307C102 Equity 2,231 3.00% $ 1.324M
REVOLUTION MEDICINES INC RVMD 76155X100 Equity 6,739 2.70% $ 1.188M
IDEXX LABORATORIES INC IDXX 45168D104 Equity 1,591 2.50% $ 1.111M
CENCORA INC COR 03073E105 Equity 2,736 2.20% $ 954.098K
UNITEDHEALTH GROUP INC UNH 91324P102 Equity 1,867 1.70% $ 756.378K
NATERA INC NTRA 632307104 Equity 2,321 1.70% $ 749.544K
SUPERNUS INC SUPN 45579U109 Equity 25,554 1.70% $ 746.177K
ABBVIE INC ABBV 00287Y109 Equity 2,420 1.60% $ 712.569K
ABIVAX SA-ADR ABVX 00370M103 Equity 7,743 1.60% $ 698.419K
HEALTHEQUITY INC HQY 42226A107 Equity 6,662 1.60% $ 686.519K
INTUITIVE SURGICAL INC ISRG 46120E602 Equity 1,541 1.50% $ 677.87K
PTC THERAPEUTICS INC PTCT 69366J200 Equity 9,930 1.40% $ 629.165K
DANAHER CORP DHR 235851102 Equity 2,524 1.30% $ 585.972K
GLAUKOS CORP GKOS 377322102 Equity 2,248 1.30% $ 553.075K
XENON PHARMACEUTICALS INC XENE 98420N105 Equity 13,433 1.20% $ 550.686K
Cash and Other Assets Less Liabilities
Cash — 1.10% —
LEGEND BIOTECH CORP-ADR LEGN 52490G102 Equity 24,327 1.00% $ 451.023K
VERTEX PHARMACEUTICALS INC VRTX 92532F100 Equity 817 1.00% $ 443.321K
IRHYTHM HOLDINGS INC IRTC 450056106 Equity 4,641 1.00% $ 434.212K
AXSOME THERAPEUTICS INC AXSM 05464T104 Equity 2,908 1.00% $ 419.828K
VIATRIS INC VTRS 92556V106 Equity 19,123 0.90% $ 395.272K
MCKESSON CORP MCK 58155Q103 Equity 363 0.90% $ 390.969K
PRAXIS PRECISION MEDICINES I PRAX 74006W207 Equity 1,173 0.90% $ 380.943K
RADNET INC RDNT 750491102 Equity 4,944 0.90% $ 375.942K
TANGO THERAPEUTICS INC TNGX 87583X109 Equity 14,086 0.80% $ 350.037K
ENLIVEN THERAPEUTICS INC ELVN 29337E102 Equity 6,976 0.80% $ 337.011K
ORUKA THERAPEUTICS INC ORKA 687604108 Equity 3,145 0.70% $ 330.194K
SPYRE THERAPEUTICS INC SYRE 00773J202 Equity 3,207 0.70% $ 330.032K
RELAY THERAPEUTICS INC RLAY 75943R102 Equity 13,489 0.60% $ 243.881K
DIANTHUS THERAPEUTICS INC DNTH 252828108 Equity 2,487 0.50% $ 229.998K
BRIGHTSPRING HEALTH SERVICES BTSG 10950A106 Equity 3,128 0.50% $ 223.496K
PALVELLA THERAPEUTICS INC PVLA 697947109 Equity 1,455 0.50% $ 222.877K
ERASCA INC ERAS 29479A108 Equity 13,905 0.50% $ 221.929K
ADAPTIVE BIOTECHNOLOGIES ADPT 00650F109 Equity 7,323 0.50% $ 215.882K
KRYSTAL BIOTECH INC KRYS 501147102 Equity 656 0.50% $ 200.526K
SOPHIA GENETICS SA SOPH H82027105 Equity 23,315 0.40% $ 183.256K
10X GENOMICS INC-CLASS A TXG 88025U109 Equity 2,889 0.40% $ 170.74K
HEALTH CATALYST INC HCAT 42225T107 Equity 119,131 0.40% $ 162.018K
INVENTIVA SA - ADR IVA 46124U107 Equity 32,662 0.30% $ 126.729K

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up